dihydroergotamine nasal Migranal
Selected indexed studies
- Dihydroergotamine. (, 2006) [PMID:34554670]
- Headache. (West J Med, 1994) [PMID:7975570]
- The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. (Headache, 2015) [PMID:25600718]
_Worker-drafted node — pending editorial review._
Connections
dihydroergotamine nasal Migranal is a side effect of
Sources
- The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. (2015) pubmed
- Dihydroergotamine mesylate nasal spray: an acute treatment option for migraine in adults. (2024) pubmed
- Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study. (2024) pubmed
- Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine. (2024) pubmed
- Dihydroergotamine. (2006) pubmed
- Headache. (1994) pubmed
- Dihydroergotamine nasal spray. (1995) pubmed
- Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action. (2022) pubmed
- Human pharmacokinetics of dihydroergotamine administered by nasal spray. (1996) pubmed
- A new dihydroergotamine nasal spray (Trudhesa) for migraine. (2021) pubmed